Trial reportThe Kaohsiung journal of medical sciences2011
Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome.
Trial report in The Kaohsiung journal of medical sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 30 citations in OpenAlex.
- Promising Experimental Treatment in Animal Models and Human Studies of Interstitial Cystitis/Bladder Pain Syndrome.International journal of molecular sciences · 2024Review
- Review
- Nano-Formulation Based Intravesical Drug Delivery Systems: An Overview of Versatile Approaches to Improve Urinary Bladder Diseases.Pharmaceutics · 2022Review
- Current Pharmacologic Approaches in Painful Bladder Research: An Update.International neurourology journal · 2017Review
- Advances in diagnosis and treatment of interstitial cystitis/painful bladder syndrome.Current infectious disease reports · 2015Article
- Liposomal inhibition of acrolein-induced injury in rat cultured urothelial cells.International urology and nephrology · 2014Article
- Single compartment drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Painful bladder syndrome: an update and review of current management strategies.Current urology reports · 2014Review
- Intravesical instillation of pentosan polysulfate encapsulated in a liposome nanocarrier for interstitial cystitis.American journal of clinical and experimental urology · 2014Article
- Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis/painful bladder syndrome.ISRN pharmacology · 2014Review
- CUA guideline: Diagnosis and treatment of interstitial cystitis/bladder pain syndrome.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaArticle
- Review: Application of Nanoparticles in Urothelial Cancer of the Urinary Bladder.Journal of medical and biological engineeringArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To present single institution open-label experience with intravesical liposomes (LPs), a mucosal protective agent, in patients with interstitial cystitis/painful bladder syndrome (IC/PBS) and to assess the safety and efficacy on IC/PBS symptoms. A total of 17 symptomatic IC/PBS patients were treated with intravesical LPs (80mg/40mL distilled water) once a week for 4 weeks (n=12) or twice a week treatment for 4 weeks (n=5). The primary outcome was the change in the O'Leary-Sant Symptom/Problem score and O'Leary-Sant total Score from baseline to Week 4 and Week 8. Other outcome measurements included the changes in pain scale, urgency scale, voiding log, and patient global assessment. Both weekly and biweekly LP instillation regiments were well tolerated. The incidence of urinary incontinence, retention, or unanticipated adverse changes was not noted at any dose either during the treatment or at the 4-week follow-up. The O'Leary-Sant Symptom/Problem score, O'Leary-Sant total Score, and pain score were significantly improved from baseline at both dose regimens with added benefit with the biweekly regimen. Intravesical LPs treatment is safe and its efficacy has sustained duration. Furthermore large-scale, placebo-controlled studies are warranted to assess the efficacy for this promising new treatment for IC/PBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.